No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
www.phoenixbio.co.jpNo one on the platform currently holds 6190.T.
No tracked institution reports a position in 6190.T as of their last filing.
No one on the platform has traded 6190.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 6190.TPhoenixBio Co., Ltd. | $300.00 | -0.66% | $1.2B | — |
| 189A.TD&m Co. Co. Ltd. | $1059.00 | +1.63% | $2.4B | — |
| 2342.TTrans Genic Inc. | $253.00 | +1.20% | $4.2B | — |
| 2435.TCEDAR.Co.,Ltd. | $207.00 | -0.48% | $2.3B | — |
| 4438.TWelby Inc. | $326.00 | +32.52% | $2.7B | — |
| 4596.TKubota Pharmaceutical Holdings Co., Ltd. | $65.00 | +0.00% | $9.1B | — |
| 4884.TKringle Pharma, Inc. | $462.00 | +5.96% | $3.7B | — |
Source: Financial Modeling Prep · peers by sector/industry